A Dark Vector Cognition product

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

66K characters. Original on sec.gov ·

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The 14 tables in Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

OVERVIEW

The following discussion is intended to further the reader’s understanding of the consolidated financial condition and results of operations of our Company. It should be read in conjunction with our condensed consolidated financial statements and accompanying notes elsewhere in this Quarterly Report on Form 10-Q (“Form 10-Q”) as well as Management’s Discussion and Analysis of Financial Condition and Results of Operations and the consolidated financial statements and accompanying notes included in our 2025 Annual Report. Our historical financial statements may not be indicative of our future performance. This Management’s Discussion and Analysis of Financial Condition and Results of Operations contains a number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risks discussed in Part I, Item 1A of our 2025 Annual Report and in Part II, Item 1A of this Form 10-Q.

Throughout this section, references to “Notes” refer to the notes to our condensed consolidated financial statements (unaudited) in Part I, Item 1 of this Form 10-Q, unless otherwise indicated.

Non-U.S. GAAP Financial Measures

For the purpose of aiding the comparison of our year-over-year results, we may refer to net sales and other financial results excluding the effects of changes in foreign currency exchange rates. Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than USD at the applicable foreign exchange rates in effect during the comparable prior-year period. We may also refer to adjusted consolidated operating profit and adjusted consolidated operating profit margin, which exclude the effects of unallocated items. The unallocated items are not representative of ongoing operations, and generally include restructuring and related charges, certain asset impairments, and other specifically identified income or expense items. The re-measured results excluding effects from currency translation, the impact from acquisitions and/or divestitures, and excluding the effects of unallocated items are not in conformity with U.S. GAAP and should not be used as a substitute for the comparable U.S. GAAP financial measures. The non-U.S. GAAP financial measures are incorporated in our discussion and analysis as management uses them in evaluating our results of operations and believes that this information provides users with a valuable insight into our overall performance and financial position.

Our Operations

We are a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. Our products include a variety of primary proprietary packaging, containment solutions, reconstitution and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services and integrated solutions. Our customers include leading biologic, generic, pharmaceutical, diagnostic, and medical device companies around the world. Our top priority is delivering quality products that meet the exact product specifications and quality standards customers require and expect. This focus on quality includes a commitment to excellence in manufacturing, scientific and technical expertise and management, which enables us to partner with our customers in order to deliver safe, effective drug products to patients quickly and efficiently.

Our business operations are organized into two global segments, Proprietary Products and West Vantage. Effective in the first quarter of 2026, the Company renamed its "Contract-Manufactured Products" reportable segment to "West Vantage™" to better align with its current strategic focus and offerings. This change in name does not affect the composition of the reportable segment, nor does it impact previously reported segment financial information. Our Proprietary Products reportable segment offers proprietary packaging, containment solutions and drug delivery systems, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our West Vantage reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, as well as combination product assembly and packaging, primarily for pharmaceutical, diagnostic, and medical device customers. We also maintain collaborations to share technologies and market products with affiliates in Japan and Mexico.

Table of Contents

Macroeconomic Factors

Beginning in 2025, the U.S. government imposed additional tariffs and trade restrictions on certain goods produced outside of the United States, and certain jurisdictions in which we operate have imposed or are considering imposing tariffs and restrictions on certain goods produced in the United States. In February 2026, the U.S. Supreme Court issued a ruling that certain tariffs imposed under the International Emergency Economic Power Act (“IEEPA”) were unauthorized. During the second quarter of 2026, the Company began applying for and receiving certain refunds for tariffs previously collected under the IEEPA. We continue to monitor this dynamic trade-policy environment, including the potential impact of existing or future tariffs, trade restrictions, retaliatory measures, available refund processes and mitigation actions. Based on information currently available, we do not expect these matters to have a material impact on our 2026 results.

We continue to monitor the conflict in the Middle East and related macroeconomic developments, including potential impacts on our operations, supply chain, transportation costs, energy costs and petroleum-based raw material inputs. While escalation or prolongation of the conflict could contribute to volatility or inflationary pressure in certain of these costs, based on information currently available and our corresponding mitigation efforts, we do not expect these matters to have a material impact on our results of operations, financial condition or liquidity. During the first nine months of 2026, our Israel-based facilities continued to operate without material disruption.

Financial Performance Summary

The following tables present a reconciliation from U.S. GAAP to non-U.S. GAAP financial measures for the three and nine months ended September 30, 2026:

($ in millions, except per share data)Operating ProfitIncome tax expenseNet incomeDiluted EPS
Three months ended September 30, 2026 U.S. GAAP$267.4$58.0$214.0$3.02
Unallocated items:
Restructuring and other charges(1)6.31.44.90.06
M&A activities, including SmartDose® 3.5mL sale(2)(54.0)(22.0)(31.9)(0.45)
Amortization of acquisition-related intangible assets(4)——0.50.01
Other(5)1.80.41.30.02
Three months ended September 30, 2026 adjusted amounts (non-U.S. GAAP)$221.5$37.8$188.8$2.66
($ in millions, except per share data)Operating profitIncome tax expenseNet incomeDiluted EPS
Nine months ended September 30, 2026 U.S. GAAP$623.6$134.9$506.8$7.09
Unallocated items:
Restructuring and other charges(1)9.3(9.9)19.10.26
M&A activities, including SmartDose® 3.5mL sale(2)(45.7)(20.2)(25.5)(0.36)
Cost-method investment activity(3)3.5—3.50.05
Amortization of acquisition-related intangible assets(4)——1.40.02
Other(5)9.22.17.20.10
Nine months ended September 30, 2026 adjusted amounts (non-U.S. GAAP)$599.9$106.9$512.5$7.16

Table of Contents

The following tables present a reconciliation from U.S. GAAP to non-U.S. GAAP financial measures for the three and nine months ended September 30, 2025:

($ in millions, except per share data)Operating ProfitIncome tax expenseNet incomeDiluted EPS
Three months ended September 30, 2025 U.S. GAAP$167.6$34.0$140.0$1.92
Unallocated items:
Restructuring and other charges(1)2.50.62.00.03
Amortization of acquisition-related intangible assets(4)——0.40.01
Three months ended September 30, 2025 adjusted amounts (non-U.S. GAAP)$170.1$34.6$142.4$1.96
($ in millions, except per share data)Operating ProfitIncome tax expenseNet incomeDiluted EPS
Nine months ended September 30, 2025 U.S. GAAP$428.3$88.3$361.6$4.97
Unallocated items:
Restructuring and other charges(1)21.93.019.00.26
Amortization of acquisition-related intangible assets(4)0.2—1.50.02
Nine months ended September 30, 2025 adjusted amounts (non-U.S. GAAP)$450.4$91.3$382.1$5.25

(1)During the three and nine months ended September 30, 2026, the Company recorded pre-tax charges of $6.3 million and $9.3 million, respectively, related to our two existing restructuring programs: (i) $5.8 million and $7.7 million, respectively, within other expense (income), related to severance and retention benefit charges and the acceleration of depreciation and lease costs in connection with the Company's January 2025 restructuring plan and (ii) $0.5 million and $1.6 million, respectively, within selling, general and administrative expenses, for professional services relating to our 2024 plan to optimize the legal structure of the Company and its subsidiaries. In addition, we recorded a one-time tax cost of $12.0 million associated with an internal legal entity restructuring which occurred in the first quarter of 2026. During the three and nine months ended September 30, 2025, the Company recorded pre-tax charges of $2.5 million and $21.9 million, respectively, related to our two existing restructuring programs: (i) $0.9 million and $17.5 million, respectively, within other expense (income), related to severance, acceleration of depreciation and lease costs in connection with the Company's January 2025 restructuring plan and (ii) $1.6 million and $4.4 million, respectively, within selling, general and administrative expenses, for professional services relating to our 2024 plan to optimize the legal structure of the Company and its subsidiaries. In addition, we recorded income tax charges of $2.0 million in the first quarter of 2025, related primarily to withholding tax and capital gains incurred in executing our plan to optimize our legal structure.

(2)During the three and nine months ended September 30, 2026, the Company recorded pre-tax benefit of $54.0 million and $45.7 million, respectively, related to M&A activities, primarily related to the Company's agreement to sell its SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie. The net benefit is composed of a net gain on the sale of its SmartDose® 3.5mL On-Body Delivery System assets of $55.7 million for the three and nine months ended September 30, 2026 within other expense (income). The Company recorded a one-time tax cost of $22.4 million associated with the gain on the sale of SmartDose® 3.5mL On-Body Delivery System. The Company recorded a net benefit of $1.9 million and net charges of $0.3 million, respectively, within other expense (income), related to employee benefits in connection with the sale agreement. The Company recorded the remaining $3.6 million and $9.7 million, respectively, within selling, general and administrative expenses, relating to professional services in connection with other M&A activities.

Table of Contents

(3)During the nine months ended September 30, 2026, the Company recorded cost-method investment impairment charges of $3.5 million within other expense (income).

(4)During the three and nine months ended September 30, 2026, the Company recorded $0.5 million and $1.4 million, respectively, of amortization expense in association with an acquisition of increased ownership interest in Daikyo. During the three and nine months ended September 30, 2025, the Company recorded $0.0 million and $0.2 million, respectively, of amortization expense within selling, general and administrative expenses associated with an intangible asset acquired during the second quarter of 2020. During the three and nine months ended September 30, 2025, the Company recorded $0.4 million and $1.3 million, respectively, of amortization expense in association with an acquisition of increased ownership interest in Daikyo.

(5)Other includes nonrecurring professional fees associated with various items including certain legal matters and our cybersecurity incident from May 2026. These charges are recorded within selling, general and administrative expenses.

RESULTS OF OPERATIONS

We evaluate the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that we consider not representative of ongoing operations. Such items are referred to as other unallocated items for which further information can be found above in the reconciliation from U.S. GAAP to non-U.S. GAAP financial measures.

Percentages in the following tables and throughout the Results of Operations section may reflect rounding adjustments.

Net Sales

The following table presents net sales, consolidated and by reportable segment, for the three months ended September 30, 2026 and 2025:

Consolidated Net Sales20262025ChangePercentage Change
Reported net sales$874.5$804.6$69.98.7%
Less: Foreign exchange(4.0)—(4.0)
SmartDose® 3.5mL transaction(11.8)(29.8)18.0
Organic net sales$866.7$774.8$91.911.9%
Proprietary Products Net Sales20262025ChangePercentage Change
Reported net sales$728.8$647.5$81.312.6%
Less: Foreign exchange(3.0)—(3.0)
SmartDose® 3.5mL transaction(11.8)(29.8)18.0
Organic net sales$720.0$617.7$102.316.6%
West Vantage Net Sales20262025ChangePercentage Change
Reported net sales$145.7$157.1$(11.4)(7.3)%
Less: Foreign exchange(1.0)—(1.0)
Organic net sales$146.7$157.1$(10.4)(6.6)%

Table of Contents

Consolidated net sales increased by $69.9 million, or 8.7%, for the three months ended September 30, 2026, as compared to the same period in 2025, including an unfavorable foreign currency translation impact of $4.0 million and a reduction in SmartDose® 3.5mL product revenue of $18.0 million due to our sale of the product line to AbbVie on July 1, 2026. Excluding foreign currency translation effects and the impact of SmartDose® 3.5mL, consolidated net sales for the three months ended September 30, 2026 organically increased by $91.9 million, or 11.9%, as compared to the same period in 2025. Volume and mix contributed $58.3 million of growth in the three months ended September 30, 2026, while sales price increases contributed $33.6 million.

Proprietary Products – Proprietary Products net sales increased by $81.3 million, or 12.6%, for the three months ended September 30, 2026, as compared to the same period in 2025, including an unfavorable foreign currency translation impact of $3.0 million. Excluding foreign currency translation effects and SmartDose® 3.5mL product revenue reduction of $18.0 million, net sales for the three months ended September 30, 2026 increased by $102.3 million, or 16.6%, as compared to the same period in 2025. Increased sales of HVP components contributed approximately 13 percentage points of organic sales growth and sales of HVP delivery devices contributed a further 3 percentage points. Sales of HVP components increased $79.1 million, or 20.3%, excluding foreign currency translation effects. This increase in HVP components sales was driven by continued strong customer demand for both Biologics and GLP-1 products as well as sales price increases. Sales of HVP delivery devices increased $18.3 million, or 26.4%, excluding foreign currency translation effects and the impact of SmartDose® 3.5mL. The increase in HVP delivery devices was driven primarily by customer demand for Daikyo Crystal Zenith® and Administration Systems. Sales of Standard Products increased by $4.9 million, or 3.1%, excluding foreign currency translation adjustments.

West Vantage – West Vantage net sales decreased by $11.4 million, or 7.3%, for the three months ended September 30, 2026, as compared to the same period in 2025, including an unfavorable foreign currency translation impact of $1.0 million. Excluding foreign currency translation effects, net sales for the three months ended September 30, 2026 decreased by $10.4 million, or 6.6%, as compared to the same period in 2025. The decrease was driven by the planned expiration of a continuous glucose monitoring customer contract at one of our facilities, offset by sales price increases and increases in sales of self-injection devices for diabetes and obesity and device components.

The following table presents net sales, consolidated and by reportable segment, for the nine months ended September 30, 2026 and 2025:

Consolidated Net Sales20262025ChangePercentage Change
Reported net sales$2,591.7$2,269.1$322.614.2%
Less: Foreign exchange44.5—44.5
SmartDose® 3.5mL transaction(11.8)(29.8)18.0
Organic net sales$2,535.4$2,239.3$296.113.2%
Proprietary Products Net Sales20262025ChangePercentage Change
Reported net sales$2,145.7$1,830.3$315.417.2%
Less: Foreign exchange36.5—36.5
SmartDose® 3.5mL transaction(11.8)(29.8)18.0
Organic net sales$2,097.4$1,800.5$296.916.5%
West Vantage Net Sales20262025ChangePercentage Change
Reported net sales$446.0$438.8$7.21.6%
Less: Foreign exchange8.0—8.0
Organic net sales$438.0$438.8$(0.8)(0.2)%

Table of Contents

Consolidated net sales increased by $322.6 million, or 14.2%, for the nine months ended September 30, 2026, as compared to the same period in 2025, including a favorable foreign currency translation impact of $44.5 million. Excluding foreign currency translation effects and the reduction in SmartDose® 3.5mL product revenue of $18.0 million for the three months ended September 30, 2026 due to our sale of the product line to AbbVie on July 1, 2026, consolidated net sales for the nine months ended September 30, 2026 increased by $296.1 million, or 13.2%, as compared to the same period in 2025. Volume and mix contributed $208.0 million of growth in the nine months ended September 30, 2026, while sales price increases contributed $88.1 million.

Proprietary Products – Proprietary Products net sales increased by $315.4 million, or 17.2%, for the nine months ended September 30, 2026, as compared to the same period in 2025, including a favorable foreign currency translation impact of $36.5 million. Excluding foreign currency translation effects and the reduction in SmartDose® 3.5mL product revenue, net sales for the nine months ended September 30, 2026 increased by $296.9 million, or 16.5%, as compared to the same period in 2025. Sales of HVP components increased $216.0 million, or 20.4%, excluding foreign currency translation effects. The increase in HVP components sales was driven by continued strong customer demand for Biologics products and GLP-1 products as well as sales price increases. Sales of HVP delivery devices increased $74.3 million, or 27.9%, excluding foreign currency translation effects and excluding the reduction in SmartDose® 3.5mL product revenue. The increase in HVP delivery devices was driven by higher market demand for self-injection devices in the first half of 2026, higher sales of Daikyo Crystal Zenith®, and sales price increases. Sales of Standard Products increased by $6.6 million, or 1.4%, excluding foreign currency translation adjustments.

West Vantage – West Vantage net sales increased by $7.2 million, or 1.6%, for the nine months ended September 30, 2026, as compared to the same period in 2025, including a favorable foreign currency translation impact of $8.0 million. Excluding foreign currency translation effects, net sales for the nine months ended September 30, 2026 decreased by $0.8 million, or 0.2%, as compared to the same period in 2025. The decrease was primarily driven by the planned expiration of a continuous glucose monitoring customer contract at one of our facilities in June, offset by sales price increases and an increase in sales of self-injection devices for diabetes and obesity and device components.

Gross Profit

The following table presents gross profit and related gross profit margins, consolidated and by reportable segment:

Three Months Ended September 30,Nine Months Ended September 30,
($ in millions)2026202520262025
Proprietary Products:
Gross profit$323.4$264.0$904.5$722.5
Gross profit margin44.4%40.8%42.2%39.5%
West Vantage:
Gross profit$24.0$30.3$68.5$77.6
Gross profit margin16.5%19.3%15.4%17.7%
Consolidated gross profit$347.4$294.3$973.0$800.1
Consolidated gross profit margin39.7%36.6%37.5%35.3%

Consolidated - Consolidated gross profit increased by $53.1 million, or 18.0%, for the three months ended September 30, 2026, as compared to the same period in 2025, including an unfavorable foreign currency translation impact of $2.5 million for the three months ended September 30, 2026, as compared to the same period in 2025. Consolidated gross profit margin increased by 3.1 percentage points for the three months ended September 30, 2026, as compared to the same period in 2025.

Table of Contents

Consolidated gross profit increased by $172.9 million, or 21.6%, for the nine months ended September 30, 2026, as compared to the same period in 2025, including a favorable foreign currency translation impact of $16.5 million for the nine months ended September 30, 2026, as compared to the same period in 2025. Consolidated gross profit margin increased by 2.2 percentage points for the nine months ended September 30, 2026, as compared to the same period in 2025.

Proprietary Products - Proprietary Products gross profit increased by $59.4 million, or 22.5%, for the three months ended September 30, 2026, as compared to the same period in 2025, including an unfavorable foreign currency translation impact of $2.4 million. Proprietary Products gross profit margin increased by 3.6 percentage points for the three months ended September 30, 2026, as compared to the same periods in 2025, due primarily to favorable sales mix of HVP components, including GLP-1 products, as well as sales price increases. These were partially offset by inflationary pressures and plant costs.

Proprietary Products gross profit increased by $182.0 million, or 25.2%, for the nine months ended September 30, 2026, as compared to the same period in 2025, including a favorable foreign currency translation impact of $15.2 million. Proprietary Products gross profit margin increased by 2.7 percentage points for the nine months ended September 30, 2026, as compared to the same periods in 2025, due primarily to favorable sales mix of HVP components, including GLP-1 products, and sales price increases. These were offset by inflationary pressures on our cost base and plant performance.

West Vantage - West Vantage gross profit decreased by $6.3 million, or 20.8%, for the three months ended September 30, 2026, as compared to the same period in 2025, including an unfavorable foreign currency translation impact of $0.1 million. West Vantage gross profit margin decreased by 2.8 percentage points for the three months ended September 30, 2026, as compared to the same period in 2025, due to product mix, inflationary pressures on our plant spend, and plant ramp up costs related to our drug handling programs, partially offset by sales price increases.

West Vantage gross profit decreased by $9.1 million, or 11.7%, for the nine months ended September 30, 2026, as compared to the same period in 2025, including a favorable foreign currency translation impact of $1.3 million. West Vantage gross profit margin decreased by 2.3 percentage points for the nine months ended September 30, 2026, as compared to the same period in 2025, due to inefficiencies associated with production downtime related to the Company’s May 2026 cyber incident, as well as inflationary pressures on our plant spend, partially offset by sales price increases.

Research and Development (“R&D”) Costs

The following table presents consolidated R&D costs:

Three Months Ended September 30,Nine Months Ended September 30,
($ in millions)2026202520262025
Consolidated R&D costs$18.3$17.1$53.8$52.5

Consolidated R&D costs increased by $1.2 million, or 7.0%, and $1.3 million, or 2.5%, for the three and nine months ended September 30, 2026, respectively, as compared to the three and nine months ended September 30, 2025. The increase in R&D spend is associated with our investment in (1) primary injectables in elastomeric components, formulation development & packaging and (2) drug containment systems, self-injection systems, and drug administration consumables.

All of the R&D costs incurred in the three and nine months ended September 30, 2026 and 2025 related to Proprietary Products.

Table of Contents

Selling, General and Administrative (“SG&A”) Costs

The following table presents SG&A costs, consolidated and by reportable segment and corporate and unallocated items:

Three Months Ended September 30,Nine Months Ended September 30,
($ in millions)2026202520262025
Proprietary Products$74.5$65.6$209.0$187.4
West Vantage8.17.524.222.1
Corporate and unallocated items30.329.696.877.1
Consolidated SG&A costs$112.9$102.7$330.0$286.6
SG&A as a % of net sales12.9%12.8%12.7%12.6%

Consolidated - Consolidated SG&A costs increased by $10.2 million, or 9.9%, for the three months ended September 30, 2026, as compared to the same period in 2025, including a favorable foreign currency translation impact of $0.1 million.

Consolidated SG&A costs increased by $43.4 million, or 15.1%, for the nine months ended September 30, 2026, as compared to the same period in 2025, including an unfavorable foreign currency translation impact of $2.7 million.

Proprietary Products - Proprietary Products SG&A costs increased by $8.9 million, or 13.6%, for the three months ended September 30, 2026, as compared to the same period in 2025, including a favorable foreign currency translation impact of $0.1 million, due primarily to higher annual incentive compensation from a higher projected incentive payout compared to the same period in 2025, increased salaries and wages due to headcount increases and increased professional fees, which contributed approximately 6%, 4% and 2%, respectively, to the SG&A cost increases.

Proprietary Products SG&A costs increased by $21.6 million, or 11.5%, for the nine months ended September 30, 2026, as compared to the same period in 2025, including an unfavorable foreign currency translation impact of $2.5 million. Proprietary Products SG&A costs increased due primarily to higher annual incentive compensation from a higher projected incentive payout compared to the same period in 2025 and increased salaries and wages due to headcount increases, each of which contributed approximately 4% of the SG&A cost increases.

West Vantage - West Vantage SG&A costs increased by $0.6 million, or 8.0%, for the three months ended September 30, 2026, as compared to the same period in 2025, due primarily to increased salary and wages due to annual inflationary increases.

West Vantage SG&A costs increased by $2.1 million, or 9.5%, for the nine months ended September 30, 2026, as compared to the same period in 2025, including an unfavorable foreign currency translation impact of $0.2 million, due primarily to increased salary and wages due to annual inflationary increases and higher annual incentive compensation from a higher projected incentive payout compared to the same period in 2025.

Corporate and unallocated items - Corporate and unallocated SG&A costs increased by $0.7 million, or 2.4%, for the three months ended September 30, 2026, as compared to the same period in 2025. During the three months ended September 30, 2026, the Company recorded expense within SG&A on the following unallocated items: (i) expense of $1.8 million related to nonrecurring professional fees associated with various items including certain legal matters and our cybersecurity incident from May 2026 and (ii) expense of $3.6 million relating to professional services in connection with the Company's agreement to sell its SmartDose® 3.5mL On-Body Delivery System and other M&A activities, which were not recorded during the same period in 2025. These increases were partially offset by a decrease in charges related to stock-based compensation in the three months ended September 30, 2026, as compared to the same period in 2025, of approximately $4 million, and decreased general corporate costs. See the Financial Performance Summary section above for further details.

Table of Contents

Corporate and unallocated SG&A costs increased by $19.7 million, or 25.6%, for the nine months ended September 30, 2026, as compared to the same period in 2025. During the nine months ended September 30, 2026, the Company recorded expense within SG&A on the following unallocated items: (i) expense of $9.2 million related to nonrecurring professional fees associated with various items including certain legal matters and our cybersecurity incident from May 2026 and (ii) expense of $9.7 million relating to professional services in connection with the Company's agreement to sell its SmartDose® 3.5mL On-Body Delivery System and other M&A activities, which were not recorded during the same period in 2025. Additionally, the Company recorded additional charges related to stock-based compensation in the nine months ended September 30, 2026, as compared to the same period in 2025, of approximately $5 million related to improved financial performance metrics and increased mark-to-market charges. These increases were partially offset by decreased general corporate costs. See the Financial Performance Summary section above for further details.

Other Expense (Income)

The following table presents other income and expense items, consolidated and by reportable segment, corporate and unallocated items:

Expense (Income)Three Months Ended September 30,Nine Months Ended September 30,
($ in millions)2026202520262025
Proprietary Products$—$6.1$10.0$15.1
West Vantage0.40.50.31.9
Corporate and unallocated(51.6)0.3(44.7)15.7
Consolidated other expense (income)$(51.2)$6.9$(34.4)$32.7

Other expense and income items consist of restructuring and related charges, foreign exchange transaction gains and losses, contingent consideration, gains and losses on oil hedges, asset impairments and miscellaneous income and charges.

Consolidated - Consolidated other expense (income) changed by $58.1 million for the three months ended September 30, 2026, as compared to the same period in 2025, due to the factors described below.

Consolidated other expense (income) changed by $67.1 million for the nine months ended September 30, 2026, as compared to the same period in 2025, due to the factors described below.

Proprietary Products - Proprietary Products other expense (income) changed by $6.1 million for the three months ended September 30, 2026, as compared to the same period in 2025, due primarily to decreased contingent consideration expense and increased gains on oil hedges recorded in the three months ended September 30, 2026, as compared to the same period in 2025.

Proprietary Products other expense (income) changed by $5.1 million for the nine months ended September 30, 2026, as compared to the same period in 2025, due primarily to increased gains on oil hedges and decreased contingent consideration expense in the nine months ended September 30, 2026, as compared to the same period in 2025.

West Vantage - West Vantage other expense (income) changed by $0.1 million for the three months ended September 30, 2026, as compared to the same period in 2025, due primarily to foreign exchange gains being recorded in the three months ended September 30, 2026, as compared to foreign exchange losses being recorded in the same period in 2025.

West Vantage other expense (income) changed by $1.6 million for the nine months ended September 30, 2026, as compared to the same period in 2025, due primarily to foreign exchange gains being recorded in the nine months ended September 30, 2026, as compared to foreign exchange losses being recorded in the same period in 2025.

Table of Contents

Corporate and unallocated items - Corporate and unallocated items changed by $51.9 million for the three months ended September 30, 2026, as compared to the same period in 2025, due primarily to the Company recording a net gain on the sale of its SmartDose® 3.5mL On-Body Delivery System assets of $55.7 million. The gain on sale was partially offset by restructuring and other charges of $3.9 million within the three months ended September 30, 2026, as compared to $0.9 million being recorded during the same period in 2025. The Company's 2026 restructuring and other charges within other expense (income) were (i) $5.8 million related to the acceleration of depreciation and lease costs in connection with the Company's January 2025 restructuring plan and (ii) a net benefit of $1.9 million related to employee benefit costs in connection with the Company's agreement to sell its SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie. The Company's 2025 restructuring and other charges within other expense (income) were $0.9 million related to severance, acceleration of depreciation and lease costs in connection with the Company's January 2025 restructuring plan.

Corporate and unallocated items changed by $60.4 million for the nine months ended September 30, 2026, as compared to the same period in 2025, due primarily to the Company recording a net gain on the sale of its SmartDose® 3.5mL On-Body Delivery System assets of $55.7 million. Additionally, the Company recorded restructuring and other charges during 2025 within other expense (income) of $17.5 million related to severance and retention benefits and acceleration of depreciation and lease costs in connection with the Company's January 2025 restructuring plan. The Company's 2026 restructuring and other charges within other expense (income) were (i) $7.7 million related to severance, acceleration of depreciation and lease costs in connection with the Company's January 2025 restructuring plan and (ii) $0.3 million related to employee benefit costs in connection with the Company's agreement to sell its SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie. The decrease in restructuring and other charges was partially offset by the Company recording cost-method investment impairment charges of $3.5 million during the nine months ended September 30, 2026 that did not occur in the same period in 2025.

Operating Profit

The following table presents adjusted operating profit, consolidated and by reportable segment, corporate and unallocated items:

Three Months Ended September 30,Nine Months Ended September 30,
($ in millions)2026202520262025
Proprietary Products$230.6$175.2$631.7$467.5
West Vantage15.522.344.053.6
Corporate and unallocated items21.3(29.9)(52.1)(92.8)
Consolidated operating profit$267.4$167.6$623.6$428.3
Consolidated operating profit margin30.6%20.8%24.1%18.9%
Unallocated items(45.9)2.5(23.7)22.1
Adjusted consolidated operating profit$221.5$170.1$599.9$450.4
Adjusted consolidated operating profit margin25.3%21.1%23.1%19.8%

Consolidated - Consolidated operating profit increased by $99.8 million, or 59.5%, for the three months ended September 30, 2026, as compared to the same period in 2025, including an unfavorable foreign currency translation impact of $2.3 million for the three months ended September 30, 2026, as compared to the same period in 2025.

Consolidated operating profit increased by $195.3 million, or 45.6%, for the nine months ended September 30, 2026, as compared to the same period in 2025, including a favorable foreign currency translation impact of $13.3 million for the nine months ended September 30, 2026, as compared to the same period in 2025.

Proprietary Products - Proprietary Products operating profit increased by $55.4 million, or 31.6%, for the three months ended September 30, 2026, as compared to the same period in 2025, including an unfavorable foreign currency translation impact of $2.2 million, due to the factors described above, most notably favorable sales mix of HVP components, including GLP-1 products.

Table of Contents

Proprietary Products operating profit increased by $164.2 million, or 35.1%, for the nine months ended September 30, 2026, as compared to the same period in 2025, including a favorable foreign currency translation impact of $12.2 million, due to the factors described above, most notably favorable sales mix of HVP components, including GLP-1 products.

West Vantage - West Vantage operating profit decreased by $6.8 million, or 30.5%, for the three months ended September 30, 2026, as compared to the same period in 2025, including an unfavorable foreign currency translation impact of $0.1 million, due to the factors described above, most notably inefficiencies associated with production, as well as inflationary pressures on our plant spend.

West Vantage operating profit decreased by $9.6 million, or 17.9%, for the nine months ended September 30, 2026, as compared to the same period in 2025, including a favorable foreign currency translation impact of $1.1 million, due to the factors described above, most notably inefficiencies associated with production downtime related to the Company’s May 2026 cyber incident, as well as inflationary pressures on our plant spend.

Corporate and unallocated - Excluding the unallocated items, Corporate costs decreased by $2.8 million, or 10.2%, for the three months ended September 30, 2026, as compared to the same period in 2025, due to the factors described above, most notably the decrease in expense related to stock-based compensation.

Excluding the unallocated items, Corporate costs increased by $5.1 million, or 7.2%, for the nine months ended September 30, 2026, as compared to the same period in 2025, due to the factors described above, most notably the increase in expense related to stock-based compensation.

For unallocated items, please refer to the Financial Performance Summary section above for details.

Interest Expense, Net and Interest Income

The following table presents interest expense, net, by significant component:

Three Months Ended September 30,Nine Months Ended September 30,
($ in millions)2026202520262025
Interest expense$4.4$4.2$11.9$12.5
Capitalized interest(0.6)(4.0)(3.6)(11.8)
Interest expense, net$3.8$0.2$8.3$0.7
Interest income$(4.3)$(4.7)$(13.2)$(12.4)

Interest expense, net, increased by $3.6 million and $7.6 million for the three and nine months ended September 30, 2026, respectively, as compared to the same periods in 2025, due primarily to a decrease in capitalized interest, partially offset by a decline in interest rates on the Company's Term Loan in the three and nine months ended September 30, 2026, as compared to the same periods in 2025.

Interest income decreased by $0.4 million and increased by $0.8 million for the three and nine months ended September 30, 2026, respectively, as compared to the same periods in 2025, due primarily to the Company having a lower average cash balance in the three months ended September 30, 2026 and a higher average cash balance in the nine months ended September 30, 2026, as compared to the same periods in 2025.

Other Nonoperating Expense (Income)

Other nonoperating expense (income) was $0.2 million and $0.6 million for both the three and nine months ended September 30, 2026 and 2025, respectively.

Table of Contents

Income Tax Expense

The provision for income taxes was $58.0 million and $34.0 million for the three months ended September 30, 2026 and 2025, respectively, and the effective tax rate was 21.7% and 19.8%, respectively. The increase in the effective tax rate for the three months ended September 30, 2026, as compared to the same period in 2025, is primarily due to a one-time tax cost of $22.4 million associated with the sale of SmartDose® 3.5mL On-Body Delivery System which occurred in the third quarter of 2026, partially offset by the impact of favorable changes in our geographic mix of earnings.

The provision for income taxes was $134.9 million and $88.3 million for the nine months ended September 30, 2026 and 2025, respectively, and the effective tax rate was 21.5% and 20.1%, respectively. The increase in the effective tax rate for the nine months ended September 30, 2026, as compared to the same period in 2025, is primarily due to a one-time tax cost of $12.0 million associated with an internal legal entity restructuring which occurred in the first quarter of 2026, in addition to a one-time cost of $22.4 million associated with the sale of SmartDose® 3.5mL On-Body Delivery System which occurred in the third quarter of 2026, partially offset by the impact of favorable changes in our geographic mix of earnings.

Equity in Net Income of Affiliated Companies

Equity in net income of affiliated companies was $4.3 million and $2.1 million for the three months ended September 30, 2026 and 2025, respectively. Equity in net income of affiliated companies increased by $2.2 million for the three months ended September 30, 2026, as compared to the same period in 2025, due primarily to favorable operating results at Daikyo and the Mexico affiliates.

Equity in net income of affiliated companies was $13.8 million and $10.5 million for the nine months ended September 30, 2026 and 2025, respectively. Equity in net income of affiliated companies increased by $3.3 million for the nine months ended September 30, 2026, as compared to the same period in 2025, due primarily to favorable operating results at Daikyo, partially offset by unfavorable operating results at the Mexico affiliates.

FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES

Cash Flows

The following table presents cash flow data for the nine months ended September 30:

($ in millions)20262025
Net cash provided by operating activities$403.4$503.7
Net cash used in investing activities$(7.0)$(209.8)
Net cash used in financing activities$(715.3)$(173.4)

Net Cash Provided by Operating Activities – Net cash provided by operating activities decreased by $100.3 million for the nine months ended September 30, 2026, as compared to the same period in 2025, due primarily to increases in customer accounts receivable and timing of collections as well as increased inventory levels to support our operations.

Net Cash Used in Investing Activities – Net cash used in investing activities decreased by $202.8 million for the nine months ended September 30, 2026, as compared to the same period in 2025, due primarily to the proceeds from the sale of assets of the SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie and a reduction in capital expenditures.

Net Cash Used in Financing Activities – Net cash used in financing activities increased by $541.9 million for the nine months ended September 30, 2026, as compared to the same period in 2025, due primarily to an increase in purchases under our share repurchase programs.

Table of Contents

Liquidity and Capital Resources

The table below presents selected liquidity and capital measures:

($ in millions)September 30, 2026December 31, 2025
Cash and cash equivalents$464.1$791.3
Accounts receivable, net$748.2$574.4
Inventories$464.7$443.9
Accounts payable$249.4$253.7
Debt$202.9$202.8
Equity$2,968.2$3,176.0
Working capital$1,172.2$1,323.3

Cash and cash equivalents include all instruments that have maturities of ninety days or less when purchased. Working capital is defined as current assets less current liabilities.

Cash and cash equivalents – Our cash and cash equivalents balance at September 30, 2026 consisted of cash held in depository accounts with banks around the world and cash invested in high-quality, short-term investments. The cash and cash equivalents balance at September 30, 2026 included $84.7 million of cash held by subsidiaries within the U.S., and $379.4 million of cash held by subsidiaries outside of the U.S. During the nine months ended September 30, 2026, we purchased 2,424,121 shares of our common stock under the share repurchase program at a cost of $685.3 million, or an average price of $282.68 per share.

Working capital – Working capital at September 30, 2026 decreased by $151.1 million, or 11.4%, as compared to December 31, 2025, which includes a decrease of $3.4 million due to foreign currency translation. Excluding the impact of currency exchange rates, cash and cash equivalents decreased by $318.9 million, while accounts receivable increased by $182.2 million.

The decrease in cash and cash equivalents was due to share repurchases and capital expenditures during the nine months ended September 30, 2026, partially offset by cash from operations and proceeds from the sale of assets of the SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie. The increase in accounts receivable was due to timing of sales within the third quarter of 2026 as compared to the fourth quarter of 2025, as well as timing of customer collections.

Debt and credit facilities – The total debt balance of $202.9 million at September 30, 2026 is consistent with the total debt balance of $202.8 million at December 31, 2025.

Our sources of liquidity include our multi-currency revolving credit facility. At September 30, 2026, we had no outstanding borrowings under the multi-currency revolving credit facility. At September 30, 2026, the borrowing capacity available under the multi-currency revolving credit facility, including outstanding letters of credit of $2.3 million, was $497.7 million. We do not expect any significant limitations on our ability to access this source of funds.

Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and not to exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At September 30, 2026, we were in compliance with all of our debt covenants.

We believe that cash on hand and cash generated from operations, together with availability under our multi-currency revolving credit facility, will be adequate to address our foreseeable liquidity needs based on our current expectations of our business operations, capital expenditures and scheduled payments of debt obligations.

Additionally, on October 26, 2026, the Company completed a refinancing of its senior unsecured credit facilities. See Note 8, Debt, within Item 1 of this report.

Table of Contents

Commitments and Contractual Obligations

A summary of future material cash payments resulting from commitments and contractual obligations was provided in our 2025 Annual Report. During the three months ended September 30, 2026, there were no material changes outside of the ordinary course of business to our commitments and contractual obligations.

OFF-BALANCE SHEET ARRANGEMENTS

At September 30, 2026, we had no off-balance sheet financing arrangements other than unconditional purchase obligations incurred in the ordinary course of business and outstanding letters of credit related to various insurance programs, as noted in our 2025 Annual Report.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

There have been no changes to the Critical Accounting Policies and Estimates disclosed in Part II, Item 7 of our 2025 Annual Report.

NEW ACCOUNTING STANDARDS

For information on new accounting standards, see Note 2, New Accounting Standards, within Item 1 of this report.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Our disclosure and analysis in this Form 10-Q contains some forward-looking statements that are based on management’s beliefs and assumptions, current expectations, estimates and forecasts. We also provide forward-looking statements in other materials we release to the public, as well as oral forward-looking statements. Such statements provide our current expectations or forecasts of future events. They do not relate strictly to historical or current facts. We have attempted, wherever possible, to identify forward-looking statements by using words such as “plan,” “expect,” “believe,” “intend,” “will,” “estimate,” “continue” and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance, as well as our strategy for growth, product development, market position and expenditures. All statements that address operating performance or events or developments that we expect or anticipate will occur in the future - including statements relating to sales and earnings per share growth, cash flows or uses, and statements expressing views about future operating results - are forward-looking statements.

Forward-looking statements are based on current expectations of future events. The forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance, and speak only as of their dates. Investors should realize that, if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Investors are therefore cautioned not to place undue reliance on any forward-looking statements.

The following are some important factors that could cause our actual results to differ from our expectations in any forward-looking statements:

  • sales demand and our ability to meet that demand;

  • competition from other providers in our businesses, including customers’ in-house operations, and from lower-cost producers in emerging markets, which can impact unit volume, price and profitability;

  • customers’ changing inventory requirements and manufacturing plans that alter existing orders or ordering patterns for the products we supply to them;

  • interruptions or weaknesses in our supply chain, including from reasons beyond our control such as extreme weather, longer-term climate changes, natural disasters, pandemic, war, accidental damage, or unauthorized access to our or our customers’ information and systems, which could cause delivery delays or restrict the availability of raw materials, key purchased components and finished products;

  • the timing, regulatory approval and commercial success of customer products that incorporate our products and systems;

Table of Contents

  • whether customers agree to incorporate our products and delivery systems with their new and existing drug products, the ultimate timing and successful commercialization of those products and systems, which involves substantial evaluations of the functional, operational, clinical and economic viability of our products, and the rate, timing and success of regulatory approval for the drug products that incorporate our components and systems;

  • the timely and adequate availability of filling capacity, which is essential to conducting definitive stability trials and the timing of first commercialization of customers’ products in Crystal Zenith prefilled syringes;

  • profitability, or mix, of the products sold in any reporting period, including lower-than-expected sales growth of our high-value proprietary product offerings;

  • maintaining or improving production efficiencies and overhead absorption;

  • dependence on third-party suppliers and partners, some of which are single-source suppliers of critical materials and products, including our Japanese partner and affiliate, Daikyo;

  • the loss of key personnel or highly skilled employees;

  • the availability and cost of skilled employees required to meet increased production, managerial, research and other needs, including professional employees and persons employed under collective bargaining agreements;

  • the successful and timely implementation of price increases necessary to offset rising production costs, including raw material prices, particularly petroleum-based raw materials;

  • the cost and progress of development, regulatory approval and marketing of new products;

  • our ability to obtain and maintain licenses in any jurisdiction in which we do business;

  • the relative strength of USD in relation to other currencies, particularly the Euro, SGD, the Danish Krone, Yen, Colombian Peso, Brazilian Real, and the South Korean Won; and

  • the potential adverse effects of global healthcare legislation on customer demand, product pricing and profitability.

This list sets forth many, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements. Investors should understand that it is not possible to predict or identify all of the factors and should not consider this list to be a complete statement of all potential risks and uncertainties. For further discussion of these and other factors, see the risk factors disclosed in Part I, Item 1A of our 2025 Annual Report as well as Part II, section 1A of this quarterly report.

Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Previous: Item 1. FINANCIAL STATEMENTS · Next: Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK